Review of nemonoxacin with special focus on clinical development

References

• Rice LB Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones Mayo Clin Proc 2012 2 87 198 208 22305032
   PubMed Web of Science ®Google Scholar
• Karpiuk I Tyski S Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials Przegl Epidemiol 2013 67 3 455 460 557 561 Polish [with English abstract] 24340560
   PubMedGoogle Scholar
• Arjona A Nemonoxacin Quinolone antibiotic Drugs Future 2009 3 34 196 203
   Web of Science ®Google Scholar
• Adam HJ Laing NM King CR Lulashnyk B Hoban DJ Zhanel GG In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates Antimicrob Agents Chemother 2009 53 11 4915 4920 19738018
   PubMed Web of Science ®Google Scholar
• Chen YH Liu CY Lu JJ King CH Hsueh PR In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan J Antimicrob Chemother 2009 64 6 1226 1229 19833635
   PubMed Web of Science ®Google Scholar
• Lauderdale TL Shiau YR Lai JF Chen HC King CH Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates Antimicrob Agents Chemother 2010 54 3 1338 1342 20065058
   PubMed Web of Science ®Google Scholar
• Chotikanatis K Kohlhoff SA Hammerschlag MR In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae Antimicrob Agents Chemother 2014 58 3 1800 1801 24366753
   PubMed Web of Science ®Google Scholar
• Chen YH Liu CY Ko WC Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006–2010 Eur J Clin Microbiol Infect Dis 2014 33 2 233 239 23955154
   PubMed Web of Science ®Google Scholar
• Hsu MS Liao CH Liu CY Yang CJ Huang YT Hsueh PR In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents Int J Antimicrob Agents 2011 37 3 276 278 21269811
   PubMed Web of Science ®Google Scholar
• Chung KP Tseng SP Huang YT Tsai TH Teng LJ Hsueh PR Arrival of Klebsiella pneumoniae carbapenemase (KPC)-2 in Taiwan J Antimicrob Chemother 2011 66 5 1182 1184 21393195
   PubMed Web of Science ®Google Scholar
• Yang JC Lee PI Hsueh PR In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998–2007 Eur J Clin Microbiol Infect Dis 2010 29 11 1369 1375 20658256
   PubMed Web of Science ®Google Scholar
• Liao CH Ko WC Lu JJ Hsueh PR Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan Antimicrob Agents Chemother 2012 56 7 3943 3949 22508299
   PubMed Web of Science ®Google Scholar
• Lin YC Huang YT Tsai PJ Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in Taiwan Antimicrob Agents Chemother 2011 55 4 1701 1705 21263053
   PubMed Web of Science ®Google Scholar
• Lai CC Tan CK Lin SH Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species J Antimicrob Chemother 2009 64 1 73 78 19398458
   PubMed Web of Science ®Google Scholar
• Lai CC Liu WL Ko WC Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species Antimicrob Agents Chemother 2011 55 5 2084 2091 21343461
   PubMed Web of Science ®Google Scholar
• Tan CK Lai CC Liao CH Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis J Antimicrob Chemother 2009 64 2 428 429 19454523
   PubMed Web of Science ®Google Scholar
• King CHR Lin L Leunk R In vitro resistance development to nemonoxacin for Streptococcus pneumoniae Program and abstracts of 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy October 25–28, 2008 Washington, DC Abstract C1-1971
   Google Scholar
• Li CR Li Y Li GQ In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone J Antimicrob Chemother 2010 65 11 2411 2415 20858687
   PubMed Web of Science ®Google Scholar
• Hsu CH Lin L Leunk R In vivo efficacy of nemonoxacin in a mouse protection model Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2008 54 54
   Google Scholar
• Hsu CH Lin L Leunk R In vivo efficacy of nemonoxacin in a mouse pulmonary infection model Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2008 43 43
   Google Scholar
• Lin L Chang LW Tsai CY Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers Antimicrob Agents Chemother 2010 54 1 405 410 19884368
   PubMed Web of Science ®Google Scholar
• Guo B Zhang J Yu J Wu X Shi Y Tsai CY A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharma-cokinetic study in healthy Chinese volunteers Biomed Chromatogr 2012 26 11 1333 1340 22275159
   PubMed Web of Science ®Google Scholar
• Guo B Wu X Zhang Y Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses Clin Drug Investig 2012 32 7 475 486
   PubMed Web of Science ®Google Scholar
• Chung DT Tsai CY Chen SJ Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers Antimicrob Agents Chemother 2010 54 1 411 417 19884374
   PubMed Web of Science ®Google Scholar
• Chow CP Tsai CY Yeh CF In vitro metabolism and interaction of nemonoxacin (TG-873870) on human hepatic CYP3A4 Abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy September 17–20, 2007 Chicago, IL Abstract A-27
   Google Scholar
• Wright DH Brown GH Peterson ML Rotschafer JC Application of fluoroquinolone pharmacodynamics J Antimicrob Chemother 2000 46 5 669 683 11062185
   PubMed Web of Science ®Google Scholar
• Liang W Chen YC Cao YR Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model Antimicrob Agents Chemother 2013 57 7 2942 2947 23587953
   PubMed Web of Science ®Google Scholar
• Bochud PY Moser F Erard P Community-acquired pneumonia. A prospective outpatient study Medicine (Baltimore) 2001 80 2 75 87 11307590
   PubMed Web of Science ®Google Scholar
• Falguera M Sacristán O Nogués A Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity Arch Intern Med 2001 161 15 1866 1872 11493128
   PubMedGoogle Scholar
• van Rensburg DJ Perng RP Mitha IH Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia Antimicrob Agents Chemother 2010 54 10 4098 4106 20660689
   PubMed Web of Science ®Google Scholar
• Kosinski MA Lipsky BA Current medical management of diabetic foot infections Expert Rev Anti Infect Ther 2010 8 11 1293 1305 21073293
   PubMed Web of Science ®Google Scholar